fda approval tirzepatide weight loss Retatrutide vs vs Semaglutide FDA approves weight-loss drug Zepbound

Dietary compounds and patterns associated with immune checkpoint inhibitor (ICI) outcomes in advanced non-small cell lung cancer (NSCLC)

Dehydration worsens nausea, fatigue, and constipation, creating a negative cycle that is entirely preventable

~16% on placebo in STEP trials Typical onset / first 1 to 4 weeks after starting or increasing dose Usual duration / self-limiting within 2 to 4 weeks at each dose tier Severity in trials / mostly mild to moderate (grade 1 or 2) Discontinuation rate / ~1.5% of STEP-1 participants stopped due to GI events Mechanism / GLP-1 receptor activation slows gastric emptying and alters intestinal motility Red-flag signs / blood in stool, dehydration, fever, or persistent symptoms beyond 72 hours First-line management / oral rehydration, smaller meals, temporary low-fat diet Dose adjustment / physician may pause dose escalation or reduce to prior tolerated dose Why Wegovy Causes Diarrhea Semaglutide 2.4 mg activates GLP-1 receptors throughout the gastrointestinal tract, not just in the pancreas

Strength begins returning for movements that were previously problematic

Stimulates growth and regeneration of cells

Skeletal Muscle and Cellular Regeneration Models Another area of investigation involves skeletal muscle regeneration and tissue remodeling pathways